To assess the association between hormone replacement therapy (HRT) use and breast cancer incidence following risk-reducing bilateral oophorectomy in women with BRCA pathogenic variants, highlighting the need for clarity in clinical guidelines.
Key Findings:
Estrogen-only HRT after RRBO was not associated with increased breast cancer risk, suggesting potential safety.
Progestin-containing regimens were linked to a higher breast cancer risk, indicating caution in their use.
Inconsistent results regarding specific HRT formulations and breast cancer risk were noted in smaller studies, warranting further investigation.
Interpretation:
The study provides evidence that estrogen-only HRT may be safe for women with BRCA pathogenic variants post-oophorectomy, while progestin-containing therapies may pose increased risks, necessitating further research.
Limitations:
Lack of international guidelines on HRT use in this population.
Potential biases in retrospective data collection and participant recall, as well as confounding factors that may influence outcomes.
Conclusion:
Further evaluation of HRT's role in breast cancer risk among women with BRCA variants is necessary to inform clinical decisions and improve long-term health outcomes, emphasizing the need for updated clinical guidelines.
